Roivant Sciences Ltd. (ROIV) Misses Q2 EPS by 11c

Roivant Sciences Ltd. (NASDAQ: ROIV) reported Q2 EPS of ($0.40), $0.11 worse than the analyst estimate of ($0.29). Revenue for the quarter came in at $37.1 million versus the consensus estimate of $29.11 million.

For earnings history and earnings-related data on Roivant Sciences Ltd. (ROIV) click here.

You May Also Be Interested In

• NIO Inc. (NIO) Tops Q2 EPS by 33c; offers guidance
• UBS Upgrades InterContinental Hotels Group (IHG:LN) (IHG) to Buy
• Morgan Stanley Starts ARCHION Corp (543A:JP) at Equalweight